ALT Q3 2023 Earnings — Altimmune, Inc. Revenue & Financial Results | Market Cap Arena

ALTAltimmune, Inc.

$353M

Q3 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$362,000+18000.0% YoY

Gross Profit

-$18M-4979.6% margin

Operating Income

-$23M-6226.5% margin

Net Income

-$21M-5710.2% margin

EPS (Diluted)

$-0.39

QoQ Revenue Growth

+5933.3%

Cash Flow

Operating Cash Flow

-$20M

Free Cash Flow

-$20M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$167M

Total Liabilities

$16M

Stockholders' Equity

$150M

Cash & Equivalents

$87M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$362,000	$2,000	+18000.0%
Gross Profit	-$18M	-$20M	+11.0%
Operating Income	-$23M	-$25M	+8.9%
Net Income	-$21M	-$24M	+12.1%